What this pack is
HERCEPTIN is the brand name in this record; trastuzumab is the generic name. Read both together with the dosage form (injectable product).
PACK CHECK · MARKET FIRST
HERCEPTINGeneric nametrastuzumab
Mainland China pack-name cue赫赛汀®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The FDA HERCEPTIN label describes trastuzumab as inhibiting proliferation of human tumour cells that overexpress HER2 and as mediating antibody-dependent cellular cytotoxicity (ADCC). This explains a label-described mechanism only; it does not determine whether a person's tumour meets relevant testing criteria, suitability, which trastuzumab product to use, combination treatment, or when to start/stop.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 赫赛汀®
- International brand name
- HERCEPTIN
- Generic name
- trastuzumab
- Dosage-form class
- Injection for intravenous infusion
- Route
- Intravenous infusion
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:赫赛汀®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A vial concentration, unit-per-mL value or device marking identifies the exact labelled product. It does not calculate an individual's amount, timing, administration, missed-use action, combination or switch.
150 mg is the labelled amount in each single-dose powder vial; one-vial and ten-vial cartons are pack identities, not infusion quantities. This intravenous powder vial is not a subcutaneous trastuzumab product or another HER2 medicine, and this page provides no reconstitution or dilution procedure.
2 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed U.S. public label (Genentech; updated May 2026)
Trastuzumab 150 mg lyophilised powder per single-dose vial; one-vial carton
- Product code
- NDC 50242-132-01
- Form and route
- HERCEPTIN trastuzumab lyophilised powder for intravenous infusion · intravenous infusion after reconstitution and dilution (label identity only; not a procedure instruction)
- Container
- preservative-free, white-to-pale-yellow lyophilised-powder single-dose vial
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- trastuzumab
- 150 mglabelled content per single-dose vial; not an individual's infusion amount, vial count, reconstitution or dilution plan
- Package
- 1 single-dose vials per carton
United States label · DailyMed U.S. public label (Genentech; updated May 2026)
Trastuzumab 150 mg lyophilised powder per single-dose vial; ten-vial carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 50242-132-10
- Form and route
- HERCEPTIN trastuzumab lyophilised powder for intravenous infusion · intravenous infusion after reconstitution and dilution (label identity only; not a procedure instruction)
- Container
- preservative-free, white-to-pale-yellow lyophilised-powder single-dose vial
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- trastuzumab
- 150 mglabelled content per single-dose vial; not an individual's infusion amount, vial count, reconstitution or dilution plan
- Package
- 10 single-dose vials per carton
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
HERCEPTIN label reading: a 150 mg single-dose powder vial is not a same-name subcutaneous product or another HER2 medicine
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses Genentech's May 2026 U.S. DailyMed public label for HERCEPTIN as a reading entry point. It helps check HERCEPTIN, trastuzumab, a 150 mg single-dose lyophilised-powder vial, intravenous infusion and target market; it does not turn vial strength, reconstitution text, missed-visit information or HER2 test terminology into an individual infusion, home procedure or switching plan.
- 150 mg describes total content of this exact single-dose lyophilised-powder vial; it is not an individual treatment amount, a self-calculated diluent volume or product that may be saved/shared. The label's reconstitution, dilution, infusion, storage and disposal steps are sterile medication operations for the treating facility and should not be recreated at home from a webpage.
- This is an intravenous HERCEPTIN label and has different administration instructions from subcutaneous trastuzumab products; it also states that it must not be substituted for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan. Shared trastuzumab wording, HER2 terminology or similar packages do not support self-switching, combining, catch-up use or changing a course.
- The label warns about cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal risk. With breathing difficulty, chest symptoms, marked low-blood-pressure-like illness, fever/chills, persistent cough, unusual fatigue, swelling or another acute concern, contact the oncology team promptly or use local urgent medical support; do not self-pause or restart infusions from a webpage.
- HER2 overexpression, gene amplification or a test result are conditions interpreted together by authorised testing and specialist teams in specific disease settings, not a basis for self-deciding on HERCEPTIN from one test name or value. Pathology, method, tumour type, cardiac function, prior treatment and the current target-market label must be reviewed together.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: HERCEPTIN intravenous infusionlabel ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about HERCEPTIN (trastuzumab). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
HERCEPTIN is the brand in this record and trastuzumab is the active-ingredient name. Check both with the dosage form (Injection for intravenous infusion) and the market on the actual pack.
Read the labelled strength in context
mg/mL, mg per vial or a total volume describes the labelled concentration or pack identity of an injectable product. It is not an individual infusion amount, preparation instruction or schedule.
Check the exact injection presentation
For an injectable or infusion presentation, verify the route, concentration, container and device in the exact current label. Do not transfer, share, prepare or substitute it from this page.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a severe reaction, fainting, difficulty breathing or sudden worsening symptoms around an injection or infusion, use the local treatment team or emergency service now. Do not wait for a website reply or alter preparation, infusion or another medicine yourself.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): HERCEPTIN public label (Genentech, 2026-05 updated) ↗reviewed 2026-08-20
- FDA: HERCEPTIN intravenous infusionlabel ↗reviewed 2026-08-20
HOW IT WORKS · NOT A TREATMENT PLAN
How trastuzumab works: the label describes activity against tumour cells that overexpress HER2
- “HER2,” “targeted” or “antibody” is not a basis for deciding use from an old test report, medicine name or online information. Test type, specimen, timing, target-market label, disease setting, cardiac assessment and the complete treatment plan must be confirmed together by an oncology team.
- Intravenous products, subcutaneous combination products, biosimilars and products from different markets with the same generic or a similar name cannot be assumed self-convertible, interchangeable or combinable from a mechanism page. Route, formulation ingredients, dose units and professional administration plan must each be checked.
- Mechanism also cannot explain or manage an infusion/injection reaction, breathing trouble, chest discomfort, cardiac-function-related symptoms or another acute concern. For an acute or severe issue, use the local oncology team and emergency pathway immediately rather than adjusting from a webpage.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: HERCEPTIN biologics approval letter ↗Historical public record · reviewed 2026-08-20
- FDA: HERCEPTIN intravenous infusionlabel ↗reviewed 2026-08-20
- NMPA: trastuzumab biosimilar for injectionclinical-trial guidance (2020, historical reference lead) ↗reviewed 2026-08-20
- FDA Drugs@FDA ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
HERCEPTINtrastuzumab
This page links to public primary-source material for HERCEPTIN. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the FDA label
The FDA label archive linked here lists Initial U.S. Approval: 1998. This historical locator is not a conclusion about current approval, availability, holder or another market.
FDA: HERCEPTIN intravenous-infusion label archive ↗FDA label archive version
This page links the 2026 FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
FDA: HERCEPTIN intravenous-infusion label archive ↗NMPA historical reference
A 2020 NMPA public guidance document uses Herceptin/赫赛汀 as historical background for trastuzumab biosimilar development. It is a historical search reference only, not a conclusion about current Mainland China approval, holder, labelling, supply or sale eligibility.
NMPA: trastuzumab biosimilar for injectionclinical-trial guidance (2020, historical reference lead) ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 赫赛汀®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.